Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous administration of two doses of sufentanil for hemodynamic response to laryngoscopy and tracheal intubation
IRCT20200825048515N62Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sufentanil, sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in heart rate after laryngoscopy and tracheal intubation and Change in blood pressure after laryngoscopy and tracheal intubation. Started Nov 2022; status: completed.
02
Drugs
sufentanil
Beyond the preview
Go deeper on IRCT20200825048515N62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N62.